Cullinan Therapeutics (CGEM) Enterprise Value (2020 - 2023)
Historic Enterprise Value for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to -$868.0 million.
- Cullinan Therapeutics' Enterprise Value rose 454.32% to -$868.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$868.0 million, marking a year-over-year increase of 454.32%. This contributed to the annual value of -$467.3 million for FY2022, which is 6110.02% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Enterprise Value of -$868.0 million as of Q3 2023, which was up 454.32% from -$841.8 million recorded in Q2 2023.
- Cullinan Therapeutics' Enterprise Value's 5-year high stood at -$208.9 million during Q4 2020, with a 5-year trough of -$909.3 million in Q3 2022.
- In the last 4 years, Cullinan Therapeutics' Enterprise Value had a median value of -$606.1 million in 2022 and averaged -$592.8 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 16020.84% in 2022, then skyrocketed by 454.32% in 2023.
- Over the past 4 years, Cullinan Therapeutics' Enterprise Value (Quarter) stood at -$208.9 million in 2020, then plummeted by 38.85% to -$290.1 million in 2021, then crashed by 61.1% to -$467.3 million in 2022, then crashed by 85.75% to -$868.0 million in 2023.
- Its Enterprise Value was -$868.0 million in Q3 2023, compared to -$841.8 million in Q2 2023 and -$659.3 million in Q1 2023.